Alcohol Abuse or Dependence
Conditions
Keywords
Alcohol, FGF21, Alcohol dependence
Brief summary
Plasma fibroblast growthfactor-21 (FGF21) responses to acute alcohol exposure will be evaluated in three groups: A: 15 individuals diagnosed with alcohol dependence (ICD10 code F10.2) and no alcoholic liver diseases, B: 15 healthy individuals with one or two parents with alcohol dependence, and C: 15 healthy matched controls without history of or disposition to alcohol dependence. The experimental day consists of a load of 0.5 g ethanol per kg body weight ingested from time 0-10 minutes followed by a 7 h period in which blood will be sampled with frequent intervals, rating of preference for ethanol, salt, sour, bitterly and sweets, sensations of hunger, appetite, satiety, headache, and nausea will be evaluated using visuel analogue scale and resting energy expenditure will be evaluated using indirect calorimetry.
Interventions
OTHEREthanol
Ethanol administration
Sponsors
University Hospital, Gentofte, Copenhagen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Three matched groups. Group A: participants diagnosed with alcohol dependence, group B: participants with a father diagnosed with alcohol dependence, and C: a healthy control group.
Eligibility
Sex/Gender
MALE
Age
25 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Informed consent * Caucasian males between 25 and 65 years of age * BMI between 19 and 27 kg/m2 * Normal haemoglobin * Normal fasting plasma glucose concentration (\< 6 mmol/l) and normal glycated haemoglobin A1c (HbA1c) (\< 42 mmol/mol) Participants with a father diagnosed with alcohol dependence (group B): * Father diagnosed with alcohol dependence * Weekly alcohol intake of less than 14 units of alcohol (of 12 g) * Normal Alcohol Use Disorders Identification Test (AUDIT) score Healthy participants (group C): * Weekly alcohol intake of less than 14 units of alcohol (of 12 g) * Normal AUDIT score
Exclusion criteria
* Liver disease evaluated by plasma alanine aminotransferase (ALAT) \> 3 × normal level, an international normalised ratio (INR) below normal values, or biopsy-verified alcoholic liver disease * Diabetes mellitus * Anaemia * Nephropathy * Other diseases the investigator finds disruptive for participation in the study. Participants with a father diagnosed with alcohol dependence (group B): \- Former alcohol dependence or abuse Healthy participants (group C): * First-degree relatives with diabetes, liver disease and/or alcohol dependence * Former alcohol dependence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fibroblast growthfactor-21 | One year | Plasma FGF21 concentrations, a member of the endocrine FGF-family |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glucose | One year | Plasma glucose concentrations |
| Insulin and C-peptide | One year | Serum insulin and C-peptide concentrations |
| Glucagon | One year | Plasma glucagon concentration |
| Tumor Necrosis Factor-alpha (TNF) | One year | Plasma TNF-alpha concentrations |
| Ethanol | One year | Plasma ethanol concentration |
| Interferon-gamma (INF) | One year | Plasma INF-gamma concentrations |
| Interleukine-10 (IL-10) | One year | Plasma IL-10 concentrations |
| Interleukine-8 (IL-8) | One year | Plasma IL-8 concentrations |
| Interleukine-6 (IL-6) | One year | Plasma IL-6 concentrations |
| Lipopolysaccharide Binding Protein (LBP) | One year | Plasma LBP concentrations |
Countries
Denmark
Outcome results
None listed